A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis

Study Director
T.S. Sim, M.D., Ph.D
Start Date
6 / 2017
Trial Phase
Phase II
Trial Status
Current Enrollment
48 August 2018
Target Enrollment

Interim results presented  by LegoChem Biosciences at the Working Group on New Drugs Annual Meeting in The Hague October 24, 2018.   A new group is being added at 1200 mg QD.

Developer Associations
Compound Associations